1. Tortorano, AM, et al. Candidaemia in Europe: epidemiology and resistance. International Journal of Antimicrobial Agents 2006; 27: 359–366.
2. Pfaller, MA, Diekema, DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clinical Microbiology Reviews 2007; 20: 133–163.
3. Swinne, D, et al. A one-year survey of candidemia in Belgium in 2002. Epidemiology and Infection 2004; 132: 1175–1180.
4. Barnett, JA, Payne, RW, Yarrow, D. Yeasts: Characteristics and Identification, 3rd edn. Cambridge: Cambridge University Press, 2000, p. 1140.
5. Hennequin, C, et al. Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. Journal of Clinical Microbiology 2001; 39: 551–559.
6. Clinical and Laboratory Standards Institute (CLSI). Quality control minimal inhibition concentration (MIC) limits for broth microdilution and MIC interpretive breakpoints. Supplement M44-S1. Wayne, PA: CLSI, 2006.
7. Odds, FC, Vranckx, L, Woestenborghs, F. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrobial Agents and Chemotherapy 1995; 39: 2051–2060.
8. Pfaller, MA, et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997–2000. Journal of Clinical Microbiology 2002; 40: 852–856.
9. Charlier, C, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? Journal of Antimicrobial Chemotherapy 2006; 57: 384–410.
10. Lagrou, K, et al. Fungemia at a tertiary care hospital: incidence, therapy, distribution and antifungal susceptibility of causative species. European Journal of Clinical Microbiology and Infectious Diseases 2007; 26: 541–547.
11. Swinne, D, Watelle, M, Nolard, N. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non-Candida albicans yeast isolates. Revista Iberoamericana de Micologia 2005; 22: 24–28.